Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial | Zendy

Soumya Swaminathan | Zendy; Chandrasekaran Padmapriyadarsini | Zendy; P. Venkatesan | Zendy; Gopalan Narendran | Zendy; Santosh Kumar | Zendy; S. Iliayas | Zendy; Pradeep A. Me | Zendy; Sriram Selvaraju | Zendy; N. Pooranagangadevi | Zendy; Perumal Kannabiran Bhavani | Zendy; C Ponnuraja | Zendy; Meenalochini Dilip | Zendy; Ranjani Ramachandran | Zendy

Open Access

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial

Author(s) -

Soumya Swaminathan,

Chandrasekaran Padmapriyadarsini,

P. Venkatesan,

Gopalan Narendran,

Santosh Kumar,

S. Iliayas,

Pradeep A. Me,

Sriram Selvaraju,

N. Pooranagangadevi,

Perumal Kannabiran Bhavani,

C Ponnuraja,

Meenalochini Dilip,

Ranjani Ramachandran

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir447

Subject(s) - medicine , efavirenz , nevirapine , pyrazinamide , lamivudine , ethambutol , regimen , didanosine , adverse effect , randomized controlled trial , sputum , rifampicin , tuberculosis , ritonavir , viral load , emtricitabine , immunology , hepatitis b virus , human immunodeficiency virus (hiv) , virus , antiretroviral therapy , pathology

Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB). We studied the safety and efficacy of once-daily NVP, compared with efavirenz (EFV; standard therapy); both drugs were administered in combination with 2 nucleoside reverse-transcriptase inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research